Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Cipla
Chubb
Express Scripts
Daiichi Sankyo
Harvard Business School
US Army
Cerilliant
AstraZeneca

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,743,441

« Back to Dashboard

Summary for Patent: 6,743,441
Title: Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Abstract:The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Inventor(s): Sanders; Steven W. (Salt Lake City, UT), Ebert; Charles D. (Salt Lake City, UT)
Assignee: Watson Pharmaceuticals, Inc. (Corona, CA)
Application Number:10/098,752
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,743,441

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE ➤ Sign Up
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 OTC Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,743,441

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,081,250 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,081,251 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,081,252 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Sign Up
7,029,694 Compositions and methods for transdermal oxybutynin therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Accenture
Dow
Federal Trade Commission
Colorcon
QuintilesIMS
Argus Health
Boehringer Ingelheim
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.